(NASDAQ: URGN) Urogen Pharma's forecast annual revenue growth rate of 41.27% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.74%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.09%.
Urogen Pharma's revenue in 2026 is $250,253,000.On average, 9 Wall Street analysts forecast URGN's revenue for 2026 to be $16,104,362,204, with the lowest URGN revenue forecast at $14,518,155,608, and the highest URGN revenue forecast at $17,314,371,997. On average, 9 Wall Street analysts forecast URGN's revenue for 2027 to be $26,567,243,806, with the lowest URGN revenue forecast at $22,250,054,426, and the highest URGN revenue forecast at $33,413,338,941.
In 2028, URGN is forecast to generate $33,979,841,296 in revenue, with the lowest revenue forecast at $30,719,632,501 and the highest revenue forecast at $38,779,661,255.